New Delhi: The Subject Expert Committee (SEC) on COVID-19, an expert panel of the Central Drugs Authority of India, on Friday (June 24, 2022) recommended the Serum Institute of India’s Kovovax vaccine for emergency use for children aged 7 to 11 years. Recommended Authority (EUA).
“The Subject Expert Committee of the Drug Controller General of India (DCGI) has recommended the Serum Institute of India (SII) vaccine Kovovax for children aged 7-11 years,” a source told news agency IANS.
The recommendation of the expert panel has been sent to DCGI for final approval. The two applications were submitted by Prakash Kumar Singh, director of government and regulatory affairs at the Serum Institute of India (SII), on March 16 and June 1.
However, DGCI will review the recommendation before granting it for final approval. The expert panel in its last meeting in April had sought more details on the application from Serum Institute, according to the source.
India’s drug regulator had on December 28, 2021 approved Kovovax for restricted use in emergency situations in adults and in the 12-17 age group with certain conditions on March 9.
first published:June 25, 2022, 8:19 a.m.